Point72 Asia (Singapore) Pte. Ltd. Arcellx, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $384 Billion
- Q1 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Arcellx, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 1,498 shares of ACLX stock, worth $93,714. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,498
Previous 709
111.28%
Holding current value
$93,714
Previous $39.4 Million
164.76%
% of portfolio
0.03%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding ACLX
# of Institutions
184Shares Held
43.4MCall Options Held
73.8KPut Options Held
196K-
Perceptive Advisors LLC New York, NY3.93MShares$246 Million5.74% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.82MShares$239 Million9.96% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$234 Million18.28% of portfolio
-
Black Rock Inc. New York, NY3.07MShares$192 Million0.01% of portfolio
-
Sr One Capital Management, LP2.35MShares$147 Million54.95% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.74B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...